Your browser doesn't support javascript.
loading
Experts document about an adequate utilization of SYSADOAs in controversial clinical situations.
Monfort, Jordi; Carné, Xavier; Abarca, Benjamín; Giménez, Sergio; Romera, Montserrat; Möller, Ingrid; Bibas, Marco; Vitaloni, Marianna; Batlle, Aina; Vergés, Josep.
Afiliación
  • Monfort J; Servicio de Reumatología, Parc de Salut Mar, Barcelona, Spain. Electronic address: JMonfort@parcdesalutmar.cat.
  • Carné X; Exmiembro del Servicio de Farmacologia Clínica, Hospital Clínic, Barcelona, Spain.
  • Abarca B; Centro de Salud Sagrado Corazón, Lugo, Spain.
  • Giménez S; Centro de Salud El Limonar, Málaga, Spain.
  • Romera M; Servicio de Reumatología, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain.
  • Möller I; Institut Poal de Reumatologia, Barcelona, Spain.
  • Bibas M; OAFI Foundation, Barcelona, Spain.
  • Vitaloni M; OAFI Foundation, Barcelona, Spain.
  • Batlle A; GOC Networking, Barcelona, Spain.
  • Vergés J; OAFI Foundation, Barcelona, Spain.
Reumatol Clin (Engl Ed) ; 17(10): 595-600, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34823827
ABSTRACT
BACKGROUND AND

OBJECTIVE:

SYSADOAs (Symptomatic Slow-Acting Drugs for Osteoarthritis) are natural compounds that have been shown to be useful and safe in the treatment of osteoarthritis (OA). However, their use in certain clinical situations still lacks scientific evidence and clear recommendations. The objective of this work was to learn the opinion of a group of experts regarding the appropriate use of SYSADOA in the treatment of OA in controversial clinical situations. MATERIALS AND

METHODS:

Following the Delphi technique, 206 specific consultations, structured in 24 clinical questions, were evaluated. A panel of experts composed of a total of 15 specialists, answered the two rounds of consultation through an online platform. The results were analysed and discussed in a face-to-face meeting with the coordinators and the scientific committee. According to the percentage of panellists who agreed on their findings, the results were classified in terms of unanimity, consensus, majority and discrepancy.

RESULTS:

The following points were agreed upon (1) the patient's phenotype determines the use of SYSADOAs; (2) SYSADOAs are considered appropriate in primary OA (knee, hand and hip) and in some types of secondary OA; they are not considered appropriate in OA of the shoulder, spine, ankle and erosive OA of the hands; (3) SYSADOAs may be prescribed for patients at risk of or with cardiovascular disease, digestive disease, hypertension, dyslipaemia, peripheral vascular disease, type 2 diabetes and, excluding Diacerein, for patients with oesophageal reflux. No agreement was obtained on the prescription of SYSADOAs for patients with hepatic and renal disease.

CONCLUSIONS:

There is limited literature on the use of SYSADOAs for the treatment of OA in controversial situations. Through this work it has been possible to establish the position of a group of experts regarding clinical situations for which there is no scientific evidence concerning their use. This work may contribute towards improving the management protocols of SYSADOAs in the treatment of OA and offer a useful approach in uncertain situations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoartritis de la Rodilla / Diabetes Mellitus Tipo 2 Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Reumatol Clin (Engl Ed) Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Osteoartritis de la Rodilla / Diabetes Mellitus Tipo 2 Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Reumatol Clin (Engl Ed) Año: 2021 Tipo del documento: Article
...